AVITA Medical Inc

RCEL

NASDAQ

Biotechnology

$7.85

USD

-0.16 (-2.00%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $247.72M

Volume 270.6K

Overview Charts Financials Peers Filings & News Analyst Ratings Technical Analysis

Latest News

Quantli Newsdesk

· 8 days ago

AVITA Medical Raises 2026 Guidance, Targets Q4 Breakeven

AVITA Medical reported Q2 2026 revenue of $21.7 million, up 18% year-over-year, driven by growth in RECELL and newer portfolio products. The company raised its full-year revenue guidance to $86–$89 million and expects to achieve cash-flow breakeven in Q4 2026.

RCEL

SEC Filings & Disclosures

No filings yet

Market Analysis

No market analysis yet

Similar Stocks

MGNX

MacroGenics Inc

$4.22

▲ +3.4%

AKBA

Akebia Therapeutics Inc

$0.8700

▲ +0.4%

GLSI

Greenwich Lifesciences Inc

$16.80

▲ +2.6%

ARCT

Arcturus Therapeutics Holdings Inc

$8.23

▲ +4.7%

CNXU

Conexeu Sciences Inc

$8.90

▲ +11.7%

TARA

Protara Therapeutics Inc

$3.97

▲ +0.8%

ORGO

Organogenesis Holdings Inc

$1.79

▲ +1.7%